Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Supplementary Materials Consolidated Financial Statements for the three months ended March 31, 2025 (IFRS)
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the three months ended March 31, 2025)
CHUGAI PHARMA, Jan-Mar (1Q) Net Income Increases by 31%
F. Hoffmann-La Roche Announces First Quarter Sales 2025
(Corrections) Notice of Partial Correction to "Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan"
Eli Lilly's Announcement Regarding Oral GLP-1 Orforglipron
Corporate Governance Report of CHUGAI PHARMACEUTICAL CO., LTD.
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
Position and Policy Regarding Reduction of the Investment Unit
Supplementary Materials for Consolidated Financial Statements for the Fiscal Year 2024.12 (IFRS)
Notice of Distribution of Retained Earnings
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the fiscal year 2024)
CHUGAI PHARMA, 19% Increase in Net Income for the Last Fiscal Year, Current period performance is undisclosed., Dividend Raised by 152 yen
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2024
Corporate Governance Report
CHUGAI PHARMACEUTICAL CO., LTD., July-September (3Q) Net Income Increases by 41%, Current Fiscal Year Dividend Revised from 82 yen to Undecided
Supplementary Materials for Consolidated Financial Statements for the Third Quarter of the Fiscal Year 2024.12 (IFRS)
Notice of Revisions to Dividend Forecast for Fiscal Year Ending December 31, 2024
Notice of Revisions to Financial Forecasts
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited)(for the third quarter of the fiscal year 2024)